SERA Stock Overview
A women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sera Prognostics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$8.26 |
52 Week High | US$12.36 |
52 Week Low | US$1.52 |
Beta | 1.34 |
1 Month Change | -14.67% |
3 Month Change | -14.93% |
1 Year Change | 151.06% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -30.59% |
Recent News & Updates
Recent updates
Sera Prognostics' PreTRM: A Speculative Buy In Women's Health
Mar 24Sera Prognostics: The Pregnancy Company On A Hot Streak
Jan 10Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?
Oct 03We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth
Jun 15We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate
Feb 16We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Nov 03A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening
Aug 10We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Jul 21Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation
Apr 06We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely
Dec 15Shareholder Returns
SERA | US Biotechs | US Market | |
---|---|---|---|
7D | -10.8% | 3.2% | 1.7% |
1Y | 151.1% | 6.0% | 26.3% |
Return vs Industry: SERA exceeded the US Biotechs industry which returned 7% over the past year.
Return vs Market: SERA exceeded the US Market which returned 26.1% over the past year.
Price Volatility
SERA volatility | |
---|---|
SERA Average Weekly Movement | 10.3% |
Biotechs Industry Average Movement | 11.1% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: SERA's share price has been volatile over the past 3 months.
Volatility Over Time: SERA's weekly volatility has decreased from 26% to 10% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 56 | Zhenya Lindgardt | seraprognostics.com |
Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.
Sera Prognostics, Inc. Fundamentals Summary
SERA fundamental statistics | |
---|---|
Market cap | US$273.53m |
Earnings (TTM) | -US$33.77m |
Revenue (TTM) | US$206.00k |
1,309x
P/S Ratio-8.0x
P/E RatioIs SERA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SERA income statement (TTM) | |
---|---|
Revenue | US$206.00k |
Cost of Revenue | US$165.00k |
Gross Profit | US$41.00k |
Other Expenses | US$33.82m |
Earnings | -US$33.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.03 |
Gross Margin | 19.90% |
Net Profit Margin | -16,395.15% |
Debt/Equity Ratio | 0% |
How did SERA perform over the long term?
See historical performance and comparison